
GSK CEO Transition: Balancing Legacy, Expectation and Renewal
Leadership transitions in the pharmaceutical industry carry stakes that extend far beyond shareholder headlines. The recent announcement that Emma Walmsley, CEO of GlaxoSmithKline (GSK), will step down at the end of 2025 represents one of those inflection points. Walmsley, who has guided the company since 2017, will remain through September 2026 to support continuity while Chief Commercial Officer Luke Miels takes over as CEO on January 1, 2026.